Catalent Marks 40 Years in Japan with New Investments and Country Leader - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Marks 40 Years in Japan with New Investments and Country Leader



Catalent now in its 40th year of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products in the Japanese market and has appointed Tadahiro Matsumura as Country Leader. Based in Catalent’s Tokyo office, Matsumura will be responsible for driving growth through business development activities in Japan and the surrounding region.

In addition, the company has opened a laboratory at its Kakegawa, Japan site to provide proof-of-concept support and feasibility studies for Catalent’s Zydis Orally Dispersible Tablet (ODT) technology and will also expand manufacturing capacity for its OptiGel Micro softgel technology. Zydis ODT is a freeze-dried oral dosage form that disperses in the mouth, requiring no water. The new Zydis laboratories, which will be officially opened as part of the 40th anniversary celebrations in September, is being constructed within the existing 107,000 square-foot Kakegawa facility. Catalent’s OptiGel Micro Technology uses a droplet, streamline flow that results in spherical capsules. These capsules can be sized from 1-7mm, which allows for smaller capsules to be produced when compared to the traditional rotary die process.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here